This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.

Inclusion Criteria:

• Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients < 12 years the total area will not exceed a maximum of 2% of the body surface area.
• Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate score of at least 1

Exclusion Criteria:

• Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.
• Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)

Baseline analysis population was consider the safety population. Safety population was defined as all patients who received at least one application of study drug.

One patient was randomised to placebo but never treated.

AEs were elicited from signing the informed consent to the completion of the clinical study (including the Follow up Visit) or premature patient withdrawal from the study. (10-13 days)

The safety population was defined as all patients who recieved at least one application of study drug. One patient was randomised to placebo but never received any treatment.Tthat is why there are only 205 patienst in the placebo group in the safety population.